Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.

Abstract

Bosentan is an endothelin receptor antagonist approved for treatment of pulmonary arterial hypertension. Mild liver reactions occur in about 10% of treated patients but severe hepatotoxicity is rare. We present clinical data and treatment outcome of a severe drug induced liver injury due to bosentan in a patient with non-cirrhotic portopulmonary… (More)

1 Figure or Table

Topics

  • Presentations referencing similar topics